Showing 1381-1390 of 5771 results for "".
- Eye2Gene and Heidelberg Engineering Announce Partnership at ARVO 2024https://modernod.com/news/eye2gene-and-heidelberg-engineering-announce-partnership-at-arvo-2024/2482266/Eye2Gene, an artificial intelligence research project based at University College London and Moorfields Eye Hospital, and Heidelberg Engineering have announced a partnership aimed at advancing ophthalmic diagnostics and personalized treatment approaches. Eye2Gene, wh
- Ora Inc. and Singapore Eye Research Institute Announce Partnershiphttps://modernod.com/news/ora-and-singapore-eye-research-institute-unveil-partnership-to-propel-ophthalmology-innovation-globally/2482264/Contract Research Organization (CRO) Ora Inc. announced a partnership with the Singapore Eye Research Institute (SERI) that aims to provide early-stage innovators with comprehensive research support. Financial terms of the deal were not disclosed.
- Isarna Therapeutics Announces Phase 2 Clinical Data Presentations at Upcoming Ophthalmology Conferenceshttps://modernod.com/news/isarna-therapeutics-announces-phase-2-clinical-data-presentations-at-upcoming-ophthalmology-conferences/2482263/Isarna Therapeutics announced upcoming oral presentations at the OIS Retina Innovation Summit on May 4 and the Association for Research in Vision and Ophthalmology (ARVO) meeting on May 7, both in Seattle. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, will present upd
- Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase 1/2 Trial Evaluating Gene Therapy for XLRShttps://modernod.com/news/atsena-therapeutics-announces-positive-clinical-data-from-the-first-cohort-of-phase-12-trial-evaluating-gene-therapy-for-xlrs/2482257/Atsena Therapeutics announced positive preliminary data from the first cohort of the ongoing LIGHTHOUSE study, a phase 1/2 clinical trial evaluating subretinal injection of ATSN-201 for the treatment of X-linked retinoschisis (XLRS). ATSN-201 utilizes AAV.SPR, the company’s novel sprea
- RetiSpec and Topcon Healthcare Announce Collaboration to Help Bring Eye-Based AI Diagnostic Tool to Markethttps://modernod.com/news/retispec-and-topcon-healthcare-announce-collaboration-to-help-bring-eye-based-ai-diagnostic-tool-to-market/2482256/Topcon Healthcare announced it has invested in RetiSpec and the two companies are collaborating to bring RetiSpec technology to market. The collaboration will bring neurology and eye care closer together. RetiSpec's clinically validated eye diagnostic AI aims to help healthcare
- Aurion Biotech Announces Completion of Enrollment in Phase 1/2 Clinical Trialhttps://modernod.com/news/aurion-biotech-announces-completion-of-enrollment-in-phase-12-clinical-trial/2482253/Aurion Biotech announced it has completed dosing of all subjects in its phase 1/2 clinical trial (CLARA) of AURN001, an allogeneic cell therapy for the treatment of corneal edema secondary to corneal endothelial dysfunction. AURN001 is a combination cell therapy product (biologic/d
- Bausch + Lomb Presents New Data at the Association for Research in Vision and Ophthalmology Annual Meetinghttps://modernod.com/news/bausch-lomb-presents-new-data-at-the-association-for-research-in-vision-and-ophthalmology-annual-meeting/2482250/Bausch + Lomb announced the presentation of 21 scientific poster presentations during the Association for Research in Vision and Ophthalmology (ARVO) annual meeting, which will take place in Seattle on May 5-9, 2024. The posters highlight the results of studies evaluating consumer,
- Inflammasome Therapeutics Announces First Patient Dosed in Geographic Atrophy Clinical Trialhttps://modernod.com/news/inflammasome-therapeutics-announces-first-patient-dosed-in-geographic-atrophy-clinical-trial/2482248/Inflammasome Therapeutics announced the first patient has been dosed in a first-in-class clinical trial for a sustained release implant for geographic atrophy (GA) due to age-related macular degeneration (AMD). The phase 1 trial (ClinicalTrials.gov ID NCT06164587) is sponsored by the Univers
- Bausch + Lomb Announces Results of Study Examining its New Daily Nutritional Supplement for Dry Eyeshttps://modernod.com/news/bausch-lomb-announces-results-of-study-examining-its-new-daily-nutritional-supplement-for-dry-eyes/2482244/Bausch + Lomb announced announced results of a company-sponsored study in Frontiers in Ophthalmology, which showed statistically significant results evaluating the efficacy and
- Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating Aqueous Outflow Restorative Procedure with OMNIhttps://modernod.com/news/sight-sciences-announces-the-publication-of-large-scale-real-world-migs-study-demonstrating-aqueous-outflow-restorative-procedure-with-omni/2482226/Sight Sciences announced the results as published in the American Journal of Ophthalmology (AJO) International of a large scale, comparative real-world clinical outcomes study of patients treated by three leading, minimally invasive glaucoma surgery (MIGS) technologies.